home / stock / evax / evax articles
Data from Evaxion's two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy o...
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. Digital Transformation Opportunities Corp. (NASDAQ: DTOC) rose 100.7% t...
Evaxion Biotech A/S (NASDAQ: EVAX) collaborated with Afrigen Biologics to develop a prophylactic vaccine based on Evaxion's EDEN-discovere...
News, Short Squeeze, Breakout and More Instantly...
Evaxion Biotech A/S Company Name:
EVAX Stock Symbol:
NASDAQ Market:
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...
RALEIGH, NC / ACCESSWIRE / June 21, 2024 / iAccess Alpha's "Buyside Best Ideas Virtual Summer Conference" is taking place on June 25-26, 2024. The conference begins on Tuesday, June 25, with Company presentations beginning at 9:30 a.m. Eastern Time. Company presentations will be webcast live o...
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic melanoma The findings also demonstrate strong and clinically relevant immune responses ...